Compassionate Use of Ubamatamab
Sponsor: Regeneron Pharmaceuticals
ClinicalTrials ID:NCT07502716
This program allows patients to access the investigational drug Ubamatamab through compassionate use, which is considered for individual cases under specific conditions.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The compassionate use program for Ubamatamab is designed to provide access to this investigational drug for patients who may benefit from it but do not qualify for clinical trials. This access is granted through Individual Patient Investigational New Drug (IND) applications, which are reviewed on a case-by-case basis.
Description
Compassionate use programs are special arrangements that allow patients to receive investigational drugs outside of clinical trials. In this case, Ubamatamab is being made available to patients who have no other treatment options and meet certain criteria. Each request for Ubamatamab under this program is carefully evaluated to ensure it is appropriate and safe for the patient. This process involves submitting an Individual Patient Investigational New Drug (IND) application, which is a formal request to use the drug for a specific patient. The goal is to provide potential benefits to patients who need it most, while ensuring their safety.
Eligibility Criteria
Eligibility will be determined during the application review process.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.